You are here: Home » Companies » News
Business Standard

Jubilant Life inks non-exclusive licensing pact with Gilead for Remdesivir

The drug, which is an injectable, got emergency approval from the US drug regulator recently.

Jubilant Life Sciences | Coronavirus | Lockdown

Sohini Das  |  Mumbai 

Covid-19 sample
A medic works on a sample for COVID-19 Rapid Test at a camp during the nationwide lockdown imposed in a bid to contain the spread of coronavirus, in Bhubaneswar, Monday, April 20, 2020 | Photo: PTI

on Tuesday said it entered into a non-exclusive licensing agreement with US-based Gilead Sciences to make and sell the latter’s anti-viral drug Remdesivir in 127 countries, including India. The re-purposed drug is being considered as a potential therapy for (Covid-19).

Most of these 127 countries are low-income and lower-middle income nations along with some upper-middle and high-income countries that face significant obstacles to healthcare access.

Under terms of the licensing agreement, Jubilant will have the right to receive a technology transfer of the Gilead manufacturing process and can scale up production. This would, however, be subject to approvals by regulatory authorities in the respective countries.

ALSO READ: Rs 20-trn package need of the hour, will unleash economic growth: India Inc

India can also start using the drug on patients on compassionate grounds. The government was checking with pharma on how soon the drug can be manufactured here for trials. Other drug makers from India are also estimated to be in the fray to sign licensing agreements.

Gilead had earlier indicated that it was working to build a global consortium to expand production of Remdesivir and make it available across countries. The drug, which is an injectable, got emergency approval from the US drug regulator recently. The trials show that patients administered with Remdesivir recover faster than others. However, Remdesivir remains an investigational drug and has not been approved by the

ALSO READ: Coronavirus LIVE: World's biggest package, says BJP; Congress disappointed

Commenting on the partnership, Shyam S. Bhartia, chairman and Hari S. Bhartia, co-chairman & managing director (MD), Jubilant Life Sciences, said, “We are very happy to strengthen our partnership with Gilead to licence Remdesivir, which, based on initial data, shows promise to be a potential therapy for Covid-19. We will be monitoring the clinical trials and regulatory approvals very closely and would be ready to launch the drug shortly after the required approvals. We also plan to produce the drug’s active pharmaceutical ingredient (API) in-house, helping its cost effectiveness and consistent availability.”

Gilead is known for getting into licensing agreements with other drugmakers for its patented drugs – it did the same for its hepatitis C drug sofosbuvir earlier.

ALSO READ: Surge in demand for preventive drugs seen post lockdown, Ayurveda in focus

In pandemic situations, India can also invoke its Patents Act and grant compulsory licensing provision to allow third party manufacturing of a patented drug.

stock ended at Rs 409.5 a piece, up 2.1 per cent on the on Tuesday.

First Published: Tue, May 12 2020. 23:02 IST